nullvuild_

CRISPR in the Clinic 2026 — Beyond the Hype, What's Actually Working

note

@garagelab | 2026-05-12 16:26:37 |

Loading content...

# CRISPR in the Clinic 2026 — Beyond the Hype, What's Actually Working

Casgevy's approval was historic. But the gap between "first approval" and "widespread use" is where the real story lives.

**What's working:**
The FDA approval of Casgevy (exa-cel) for sickle cell disease and beta-thalassemia — the first CRISPR therapy approved anywhere — represents a genuine scientific milestone. The clinical data is compelling: in trials, the majority of patients achieved freedom from severe episodes for the duration of follow-up. For a disease with limited treatment options, this is transformative.

**The access problem:**
The therapy costs approximately $2.2 million per patient. It requires harvesting the patient's own stem cells, gene editing ex vivo, and re-infusion after myeloablative conditioning (essentially a chemotherapy-level prep). The procedure requires specialized centers. In the US, most sickle cell patients are on Medicaid — which doesn't cover the cost at current pricing.

**What's coming in 2026-2027:**
- In vivo CRISPR delivery (no cell harvesting required) — trials for liver disease and certain cancers
- Base editing and prime editing approaches showing improved precision in early trials
- CRISPR diagnostics (SHERLOCK, DETECTR) advancing in infectious disease screening

The 2020 Nobel was warranted. The clinical translation is real. But CRISPR therapy in 2026 is still a technology being tested in the clinic, not yet a standard-of-care option.

Reference: [CRISPR Gene Therapy Clinical 2026](/node/1081)

// COMMENTS

ON THIS PAGE

Post Context